Spots Global Cancer Trial Database for mln9708
Every month we try and update this database with for mln9708 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT02477215 | Multiple Myelom... | MLN9708 Dexamethasone Bendamustine (m... Bendamustine (M... | 18 Years - | Medical College of Wisconsin | |
| STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS | NCT02586038 | Multiple Myelom... | MLN9708 Dexamethasone Cyclophosphamid... Thalidomide | 65 Years - | University of Turin, Italy | |
| Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma | NCT03731832 | Refractory Mult... | MLN9708 Pomalidomide 4 ... Dexamethasone Cyclophosphamid... | 18 Years - | GWT-TUD GmbH | |
| Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia | NCT01887587 | Relapsed or Ref... Relapsed or Ref... Mixed Phenotype... | MLN9708 Vincristine Doxorubicin Dexamethasone | 18 Years - | Medical College of Wisconsin | |
| Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma | NCT02406144 | Multiple Myelom... | MLN9708 Lenalidomide Dexamethasone | 18 Years - 67 Years | PETHEMA Foundation | |
| Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas | NCT02158975 | Lymphoma, T-Cel... | MLN9708 | 18 Years - | University of Michigan Rogel Cancer Center | |
| Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas | NCT02158975 | Lymphoma, T-Cel... | MLN9708 | 18 Years - | University of Michigan Rogel Cancer Center | |
| MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma | NCT01660997 | Multiple Myelom... | MLN9708 Dexamethasone | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies | NCT02042989 | Advanced Cancer... | MLN9708 Vorinostat | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Ixazomib and Erlotinib in Solid Tumors | NCT02942095 | Solid Tumors | Ixazomib Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age | NCT02582359 | Acute Myeloid L... | MLN9708 Cytarabine Daunorubicin | 60 Years - | Massachusetts General Hospital | |
| Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma | NCT01939899 | Follicular Lymp... | IXAZOMIB | 18 Years - | Takeda | |
| MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma | NCT02057640 | Multiple Myelom... Kahler Disease Plasma-Cell Mye... Myelomatosis | Panobinostat Dexamethasone MLN9708 | 18 Years - | Case Comprehensive Cancer Center | |
| MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma | NCT02057640 | Multiple Myelom... Kahler Disease Plasma-Cell Mye... Myelomatosis | Panobinostat Dexamethasone MLN9708 | 18 Years - | Case Comprehensive Cancer Center | |
| Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma | NCT01939899 | Follicular Lymp... | IXAZOMIB | 18 Years - | Takeda | |
| Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma | NCT02168101 | Multiple Myelom... | MLN9708 | 18 Years - 70 Years | SCRI Development Innovations, LLC | |
| STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS | NCT02586038 | Multiple Myelom... | MLN9708 Dexamethasone Cyclophosphamid... Thalidomide | 65 Years - | University of Turin, Italy | |
| Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma | NCT02168101 | Multiple Myelom... | MLN9708 | 18 Years - 70 Years | SCRI Development Innovations, LLC | |
| Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma | NCT02046070 | Multiple Myelom... | Cyclophosphamid... Ixazomib Dexamethasone | 18 Years - | Takeda | |
| Study of Ixazomib and Erlotinib in Solid Tumors | NCT02942095 | Solid Tumors | Ixazomib Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies | NCT02042989 | Advanced Cancer... | MLN9708 Vorinostat | 18 Years - | M.D. Anderson Cancer Center | |
| Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma | NCT02406144 | Multiple Myelom... | MLN9708 Lenalidomide Dexamethasone | 18 Years - 67 Years | PETHEMA Foundation | |
| Phase I Study of the Combination of MLN9708 and Fulvestrant | NCT02384746 | Breast Cancer | Fulvestrant MLN9708 | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT02477215 | Multiple Myelom... | MLN9708 Dexamethasone Bendamustine (m... Bendamustine (M... | 18 Years - | Medical College of Wisconsin | |
| Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma | NCT03422874 | Neoplasms Lymphoma | MLN9708 Nelfinavir | 18 Years - | Dartmouth-Hitchcock Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
